Corcept Therapeutics Incorporated

Corcept Therapeutics’ cortisol modulator relacorilant improved progression-free survival (PFS) and overall survival (OS) in a Phase III trial in patients with platinum-resistant ovarian cancer, paving

With sales of Korlym (mifepristone), the leading Cushing’s disease drug, forecast to start falling next year, Corcept Therapeutics Incorporated needs a new money-spinner. Thanks to a hit in the piv

Citeline · Biopharma’s Must-Know 2023-4 Catalysts Podcast Time Stamps 00:07 Introduction 00:45 Cytokinetics, Inc. ’s aficamten 01.56 Corcept Therapeutics Incorporated ’s relacorilant 03:28 Sano

The leaves are changing color and the nights drawing in – but what will the final season of the year bring for biopharma? Here, Scrip compiles the major clinical readouts that are on the way, and co